Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects—drug exposure surveillance study

We report an association found in a surveillance study which systematically evaluated combinations of specific birth defects and drugs used in the first trimester of pregnancy.

[1]  L. de Jong-van den Berg,et al.  Selection of controls in case-control studies on maternal medication use and risk of birth defects. , 2007, Birth defects research. Part A, Clinical and molecular teratology.

[2]  M. Cornel,et al.  Birth Defect and Risk Factor Surveillance in the Northern and Southwestern Netherlands , 2000, Public Health Genomics.

[3]  M. Martinez-frias,et al.  Postmarketing Analysis of Medicines , 2012, Drug safety.

[4]  B. Macmahon.  The Continuing Enigma of Pyloric Stenosis of Infancy: A Review , 2006, Epidemiology.

[5]  J. Tack,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders , 2007 .

[6]  O. Spigset,et al.  Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. , 2005, Drug safety.

[7]  B. Roth,et al.  Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor , 1996, Psychopharmacology.

[8]  A. Mitchell,et al.  Signal generation and clarification: use of case–control data , 2001, Pharmacoepidemiology and drug safety.

[9]  Mar a Luisa Mart nez-Fr as.  Postmarketing Analysis of Medicines: Methodology and Value of the Spanish Case-Control Study and Surveillance System in Preventing Birth Defects , 2007 .

[10]  M. Clementi,et al.  Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. , 2008, British journal of clinical pharmacology.

[11]  A. Mitchell,et al.  Systematic identification of drugs that cause birth defects--a new opportunity. , 2003, The New England journal of medicine.

[12]  B. Jaffe,et al.  Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[13]  S. Hernández-Díaz,et al.  Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn , 2006, The New England journal of medicine.

[14]  S. Hernández-Díaz,et al.  First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. , 2007, The New England journal of medicine.

[15]  B. Källén,et al.  No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy , 2006, International journal of medical sciences.

[16]  J. Launay,et al.  Developmentally regulated serotonin 5-HT2B receptors , 2001, International Journal of Developmental Neuroscience.

[17]  S. Vollset,et al.  Malformation surveillance and maternal drug exposure: the MADRE project. , 1994, The International journal of risk & safety in medicine.